Upstream Bio is set to deliver additional clinical findings from its Phase 2 VIBRANT trial of verekitug, aimed at treating chronic rhinosinusitis with nasal polyps. The data, which centers on a responder analysis, will be presented at the EAACI 2026 Congress in Istanbul on June 14, 2026.
Subscribe
Chronic Illness Management
Therapy Options
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Key Takeaways:
- Upstream Bio will present Phase 2 VIBRANT trial data at EAACI 2026.
- Verekitug focuses on chronic rhinosinusitis with nasal polyps (CRSwNP).
- The drug is the only known TSLP receptor antagonist in clinical development today.
- A responder analysis will highlight clinically meaningful improvements.
Upstream Bio’s Inflammatory Disease Focus
Upstream Bio, Inc. (Nasdaq: UPB) is a clinical-stage company committed to developing treatments for inflammatory conditions, particularly those affecting the respiratory system. Its latest work involves verekitug, a medication uniquely tied to the thymic stromal lymphopoietin (TSLP) receptor.
Phase 2 VIBRANT Trial Details
The VIBRANT trial investigates verekitug’s potential in patients diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP). While only limited trial details are publicly available, the company’s research aims to address severe and persistent symptoms often associated with the disease.
Presentation at EAACI 2026
Upstream Bio’s new data will debut on Sunday, June 14, 2026, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Istanbul, Turkey. Attendees will learn more about verekitug’s effects on key measures of CRSwNP and how those findings may impact future treatment.
Responder Analysis Highlights
A key feature of the presentation is the responder analysis, which shows how many patients in the trial reached clinically meaningful improvements while receiving verekitug. These findings may help illustrate the drug’s broader potential to manage CRSwNP and improve patient quality of life.
Why Verekitug Stands Out
Crucially, verekitug is the only known TSLP receptor antagonist currently under clinical development. This offers a distinctive approach to treating inflammatory conditions, setting the stage for innovative treatments and fresh hope for patients managing severe respiratory disorders.
